Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)

June 29, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search